Baidu
map

Nature:IL-1与干扰素联手调用免疫系统对抗结核病菌

2014-07-04 MedSci MedSci原创

一项最新研究定义了三个免疫力调控分子:1型干扰素、白细胞介素1与前列腺素E2之间的关系,这将有助于解释结核菌感染后为何出现不同结果。 目前全世界有几十亿人感染结核分枝杆菌(Mycobacterium tuberculosis),但是其中只有5-10%的人在临床上出现了明显症状。这就像是轮盘赌游戏,谁也不知道到底会得到什么结果。 科学家们进行了多项研究,分析发现了许多导致临床肺结核(TB)风险的

一项最新研究定义了三个免疫力调控分子:1型干扰素、白细胞介素1与前列腺素E2之间的关系,这将有助于解释结核菌感染后为何出现不同结果。

目前全世界有几十亿人感染结核分枝杆菌(Mycobacterium tuberculosis),但是其中只有5-10%的人在临床上出现了明显症状。这就像是轮盘赌游戏,谁也不知道到底会得到什么结果。

科学家们进行了多项研究,分析发现了许多导致临床肺结核(TB)风险的遗传和环境因素,了解这些因素之间如何相互作用对感染结果的影响,将有助于设计更好的治疗方法,靶向高风险因素。

来自美国NIH,巴西圣保罗大学,中国河南胸科等处的研究人员绘制出了由决定结核菌感染结果的关键因子组成的免疫网络,并从中增加宿主抗性。

研究人员发现白细胞介素1(一种能调控机体感染后免疫应答的蛋白)能帮助保护机体,免受TB感染的侵害,他们进行了细胞实验,小鼠实验,以及感染了 TB结核菌的患者实验,结果证明白介素1能诱导调控因子:前列腺素E2 (PGE2)的生成,后者限制了1型干扰素分泌,而这正与TB严重症状发生有关。

由此科学家们研究出了一种免疫治疗方法,即通过调控细胞因子干扰素(在活动性肺结核中过量存在)和白介素1(被认为有保护作用),针对小鼠肺结核模型中的先天免疫系统进行治疗。

利用PGE2和zileuton(一种通常用来治疗哮喘的,获得批准的临床药物),进行宿主导向免疫治疗,能防止感染了TB的小鼠死亡。这一方法尤其对于那些感染了具有药物抗性TB菌种的患者,他们能进行抗生素治疗的种类有限。

研究人员表示,从原则上来说,这种方法能配合标准的抗生素治疗方案进行,在未来的研究中,研究人员将在TB感染患者中检测配合这种方法进行治疗的疗效。

原始出处:

Katrin D. Mayer-Barber,Bruno B. Andrade,Sandra D. Oland,Eduardo P. Amaral,Daniel L. Barber, et al.Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk Nature 511, 99-103 doi:10.1038/nature13489

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=19531, encodeId=162d19531cd, content=很好,研究到基因位点更好, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0a31620495, createdName=fengcongzhilei, createdTime=Sun Apr 05 14:48:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10536, encodeId=3d8a1053687, content=不错不错,有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=223d105927, createdName=mao123, createdTime=Sat Jul 19 10:12:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880157, encodeId=b7a8188015e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 21 13:04:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253923, encodeId=be61125392347, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508165, encodeId=2bc1150816574, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509878, encodeId=611d15098e8f6, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
    2015-04-05 fengcongzhilei

    很好,研究到基因位点更好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=19531, encodeId=162d19531cd, content=很好,研究到基因位点更好, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0a31620495, createdName=fengcongzhilei, createdTime=Sun Apr 05 14:48:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10536, encodeId=3d8a1053687, content=不错不错,有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=223d105927, createdName=mao123, createdTime=Sat Jul 19 10:12:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880157, encodeId=b7a8188015e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 21 13:04:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253923, encodeId=be61125392347, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508165, encodeId=2bc1150816574, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509878, encodeId=611d15098e8f6, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
    2014-07-19 mao123

    不错不错,有意义的研究

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=19531, encodeId=162d19531cd, content=很好,研究到基因位点更好, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0a31620495, createdName=fengcongzhilei, createdTime=Sun Apr 05 14:48:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10536, encodeId=3d8a1053687, content=不错不错,有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=223d105927, createdName=mao123, createdTime=Sat Jul 19 10:12:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880157, encodeId=b7a8188015e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 21 13:04:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253923, encodeId=be61125392347, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508165, encodeId=2bc1150816574, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509878, encodeId=611d15098e8f6, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
    2015-03-21 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=19531, encodeId=162d19531cd, content=很好,研究到基因位点更好, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0a31620495, createdName=fengcongzhilei, createdTime=Sun Apr 05 14:48:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10536, encodeId=3d8a1053687, content=不错不错,有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=223d105927, createdName=mao123, createdTime=Sat Jul 19 10:12:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880157, encodeId=b7a8188015e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 21 13:04:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253923, encodeId=be61125392347, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508165, encodeId=2bc1150816574, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509878, encodeId=611d15098e8f6, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=19531, encodeId=162d19531cd, content=很好,研究到基因位点更好, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0a31620495, createdName=fengcongzhilei, createdTime=Sun Apr 05 14:48:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10536, encodeId=3d8a1053687, content=不错不错,有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=223d105927, createdName=mao123, createdTime=Sat Jul 19 10:12:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880157, encodeId=b7a8188015e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 21 13:04:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253923, encodeId=be61125392347, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508165, encodeId=2bc1150816574, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509878, encodeId=611d15098e8f6, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
    2014-07-06 jjjiang0202
  6. [GetPortalCommentsPageByObjectIdResponse(id=19531, encodeId=162d19531cd, content=很好,研究到基因位点更好, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0a31620495, createdName=fengcongzhilei, createdTime=Sun Apr 05 14:48:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10536, encodeId=3d8a1053687, content=不错不错,有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=223d105927, createdName=mao123, createdTime=Sat Jul 19 10:12:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880157, encodeId=b7a8188015e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 21 13:04:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253923, encodeId=be61125392347, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508165, encodeId=2bc1150816574, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509878, encodeId=611d15098e8f6, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Sun Jul 06 12:04:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
    2014-07-06 wgx309

相关资讯

EMA推荐两药治疗多重耐药结核菌感染

  2013年11月22日,欧洲药品管理局(EMA)人用药委员会(CHMP)推荐,授权Deltyba (delamanid)和对氨水杨酸(para-aminosalicylic acid)与其他抗多重耐药结核药物一起用于治疗结核。   CHMP推荐delamanid用于治疗肺部感染多重耐药结核菌的成人患者,数据显示,接受delamanid治疗的患者获益超过其风

BMJ:新型抗结核三联方案PaMZ III期临床试验即将启动

5月27日,BMJ上发布了一则新闻,全球结核病药物研发联盟(TB Alliance)宣称将于年末在非洲、亚洲、东欧和拉丁美洲的50个研究点启动一项有关新型抗结核三联方案的III期临床研究。 STAND(Shortening Treatments by Advancing Novel Drugs)研究旨在评估PaMZ方案,该方案包含2种尚未获批用于结核治疗的药物—PA-824(Pa)和莫西沙星(M

Nat Med:合成抗菌分子Q203有望治疗耐药结核病

本周的Nature Medicine报道,一种新的药物能够抑制结核分枝杆菌生长,这一发现可能会提高治疗的耐药结核病(TB)的治疗选择。 世界三分之一人口受到结核分枝杆菌的潜伏感染,每年超过百万人死于结核病。耐多药结核分枝杆菌菌株已经广泛传播,因此,开发新的和改进的药物迫在眉睫。 韩国学者Kevin Pethe及其同事筛选了巨噬细胞中的结核分枝杆菌生长抑制剂的化学库,并确定imidazopyri

中国疾控中心与Aeras签署结核疫苗研发协议

在全球性结核病变得越来越难以治疗、成本越来越高以及致死性越来越强的情况之下,中国疾病预防控制中心(中国疾控中心)和Aeras今天签署了一项旨在推进新结核病疫苗研究和发展的谅解备忘录。新的结核病疫苗为根除这种每年导致全球140万人死亡的空气传播传染病带来了希望。 尽管中国在过去30年间结核病的发病和死亡数量均大幅减少,但结核病仍然是一个威胁公众健康的重大问题,每年在中国都有超过100万的新发病例。

Nat Genet:结核病研究取得新进展

数个独立研究团队为来自世界不同地区的结核分枝杆菌进行了全基因组测序,成果于9月2日发表在《自然—遗传学》期刊上。相关研究有望为耐药性结核病疫情的出现提供新见解,并为耐药性测试和药物开发提供新标靶。【原文下载】 美国马萨诸塞州总医院教授Maha Farhat领衔的研究小组,为全球123种具有代表性的结核分枝杆菌菌株(包括耐药性菌株)进行了全基因组测序和分析。该研究小组借鉴了菌株之

京港感染医师论坛 2013:中枢神经系统感染诊治体会

11月16日,在第二届京港感染医师论坛主题报告会上,北京协和医院内科教授、博士生导师,感染内科主任,中华医学会传染病与寄生虫分会副主任委员兼艾滋病学组组长,中华医学会热带病和寄生虫分会主任委员李太生教授作了题为“中枢神经系统感染诊治体会”的报告。 李太生教授首先逐一分析了三个临床症状都为发热伴意识障碍的病例并指出只有第二个病例为脑膜炎奈瑟菌引起的中枢神经系统感染。 随后,李教授逐一讲解了细

Baidu
map
Baidu
map
Baidu
map